PIP and breast carcinoma: We used a large and well-characterized cohort of breast cancer patients who underwent anthracycline/taxane-based neoadjuvant chemotherapy (NACT) in the phase III randomized GeparTrio trial (NCT00544765) to investigate the distribution of GCDFP-15 expression in biological subtypes of breast cancer, its potential prognostic and predictive value, as well as its relationship to AR expression.